RAC1 and leukemia: From a translational perspective, combining anthracycline drugs and α2β1 integrin blockers or the design of novel agents that can induce leukemia cell death independently from the Rac1 pathway might be helpful in preventing the emergence of drug-resistant leukemic cells.